Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 33 clinical trials
The Hemophilia Inhibitor Prevention Trial

patients with severe hemophilia A.

  • 0 views
  • 21 Oct, 2021
  • 3 locations
The Hemophilia Inhibitor Eradication Trial

inhibitors in severe hemophilia A.

  • 0 views
  • 13 Nov, 2021
  • 2 locations
A Pharmacokinetic and Clotting Activity Study of FVIII-PEGLip

The purpose of this study is to demonstrate that PEGylated liposomes (PEGLip) can shield FVIII from the immune system and inhibitors, and therefore provide a prophylactic FVIII replacement therapy for patients with inhibitors to FVIII.

  • 0 views
  • 28 Oct, 2021
  • 5 locations
Study of the Efficacy and Safety PF-06741086 in Adult and Teenage Participants With Severe Hemophilia A or Moderately Severe to Severe Hemophilia B

Treatment with PF-06741086 is anticipated to demonstrate a clinically relevant advantage and/or a major contribution to patient care in comparison to current methods of treatment for hemophilia A or B because it works differently than factor replacement products and will work in the presence of inhibitors. The potential for once …

acute hemorrhage
antihemophilic factor
Factor VIII
acute bleeding
hemophilia
  • 130 views
  • 26 May, 2022
  • 59 locations
A Study of PEGylated Recombinant Factor VIII (BAX855) in Previously Untreated Young Children With Severe Hemophilia A

This study is for young children with severe hemophilia A who have previously not been treated with BAX855 or other FVIII concentrates. The main aim of the study is to check for side

immune tolerance
hemostatic
antihemophilic factor
recombinant factor viii
advate
  • 0 views
  • 26 Jan, 2022
  • 90 locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B

  • 0 views
  • 15 Apr, 2022
  • 13 locations
Fitusiran Prophylaxis in Male Pediatric Subjects Aged 1 to Less Than 12 Years With Hemophilia A or B (ATLAS-PEDS)

Primary Objective: To confirm appropriate dose levels of fitusiran when administered to male pediatric participants (ages 1 to <12 years of age) with severe hemophilia A or B

fitusiran
antihemophilic factor
severe haemophilia a
factor ix
bethesda assay
  • 82 views
  • 26 Apr, 2022
  • 13 locations
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors

Termination" from the Phase 3 Study B7841005. Approximately 145 adolescent and adult participants 12 to <75 years of age with severe hemophilia A or moderately severe to severe hemophilia B (defined as

  • 0 views
  • 25 May, 2022
  • 9 locations
Study to Test the Safety and How Well Patients With Severe Hemophilia A Respond to Treatment With BAY 2599023 (DTX 201), a Drug Therapy That Delivers a Healthy Version of the Defective Factor VIII Gene Into the Nucleus of Liver Cells Using an Altered, Non-infectious Virus (AAV) as a "Shuttle".

In this study researchers want to gather more information about safety and effectiveness of BAY 2599023 (DTX201), a drug therapy that delivers the human factor VIII gene into the human body by use of a viral vector to treat the disease. By replacing the defective gene with a healthy copy …

antihemophilic factor
bleeding tendency
severe haemophilia a
coagulation factor
  • 208 views
  • 13 May, 2022
  • 10 locations
Personalized Medicine for Canadians With Hemophilia (PMCH)

severe hemophilia A/B patients undergoing tailored prophylaxis which will enable evaluation of a combination of patient and treatment characteristics predictive of individual bleeding risk.

hemophilia
severe haemophilia a
treatment regimen
  • 4 views
  • 01 Mar, 2022
  • 5 locations